Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 56 |
| Active Pipeline (Recruiting Now) | 47 (18) |
| Completed vs Stopped Early | 3 / 6 (10.7%) |
| Median Closed Actual Enrollment | 84 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Oklahoma Health Sciences Center | Oklahoma City, OK | 39 |
| Billings Clinic Cancer Center | Billings, MT | 39 |
| Carle Cancer Center | Urbana, IL | 39 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | Phase II | RECRUITING |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase II | RECRUITING |
| NCT07293247 | A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | Phase II | RECRUITING |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer | Phase III | RECRUITING |
| NCT06661720 | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Ca | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Alliance for Clinical Trials in Oncology Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.